The ARCAN Database is Used for Retrospective Non-interventional Research Projects. The Database Collects Clinical and Laboratory Data From Patients With Lymphoid Malignancies. The Database Doesn't Require Biological Sample of Patients, it Records Only Information Based on the Patients' Medical File.
NCT03868527 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 13000
Last updated 2019-03-11
Summary
To identify the diagnostic and therapeutic approach (efficacy and toxicity) of patients with lymphoid malignant hemopathy who are managed in the hematology department.
Conditions
Interventions
- OTHER
-
Data collection
Data collection for biostatistical analysis about hematological diseases
Sponsors & Collaborators
-
Hospices Civils de Lyon
lead OTHER
Principal Investigators
-
Gilles Salles, MD · Hospices Civils de Lyon
Eligibility
- Min Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2003-01-31
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- France
Study Locations
More Related Trials
-
ACVBP Followed by ASCT in Patients With BCL-2 Positive Diffuse Large B-Cell Lymphoma
NCT00169130 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Relapsing or Refractory Chronic Lymphocytic Leukemia
NCT01488162 ·Status: COMPLETED
-
Italian Study of Patients With Lymphoma
NCT06814925 ·Status: RECRUITING
-
Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas
NCT06806488 ·Status: RECRUITING
-
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478 ·Status: COMPLETED
-
Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry
NCT04587388 ·Status: RECRUITING
-
Tumor Registry of Lymphatic Neoplasia
NCT00889798 ·Status: COMPLETED
-
ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma
NCT00144807 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I/II Study of Diffuse Large B-cell Lymphoma
NCT04856137 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Primary Mediastinal Large B-cell Lymphoma (PMBCL): Multicenter Retrospective Study
NCT05162170 ·Status: COMPLETED
-
Registry of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
NCT05832125 ·Status: UNKNOWN
-
Primary Cardiac Lymphoma: Italian Multicenter Experience
NCT05819528 ·Status: RECRUITING
-
Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia
NCT02520895 ·Status: COMPLETED
-
Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP
NCT01210287 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Procurement of Follicular B Cell Lymphoma Cells for the Purpose of Possible Use in Future Clinical Trials
NCT00487513 ·Status: COMPLETED
-
Indication to Transplant Patients With High Risk B Cells Lymphoma in Metabolic Complete Remission?
NCT03681938 ·Status: UNKNOWN
-
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma
NCT01290120 ·Status: COMPLETED ·Phase: PHASE2
-
Primary Mediastinal Large B-cell Lymphoma With CNS Involvement
NCT06024694 ·Status: ACTIVE_NOT_RECRUITING
-
B-Cell Hematologic Malignancy Vaccination Registry
NCT02298816 ·Status: WITHDRAWN
-
Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0
NCT03265158 ·Status: UNKNOWN
-
Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy
NCT03595813 ·Status: COMPLETED ·Phase: NA
-
Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma
NCT00169169 ·Status: TERMINATED ·Phase: PHASE3
-
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT05338892 ·Status: COMPLETED
-
Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans
NCT01287923 ·Status: COMPLETED
-
Observational Study for Patients With Newly Diagnosed (MCL) Not Eligible for High-dose Therapy
NCT03054883 ·Status: COMPLETED